PMV CONSUMER ACQUISITION CORP. ANNOUNCES THE SEPARATE TRADING OF ITS CLASS A COMMON STOCK AND WARRANTS, COMMENCING ON NOVEMBER 12, 2020

Palm Beach, Florida, Nov. 12, 2020 (GLOBE NEWSWIRE) — PMV Consumer Acquisition Corp. (NYSE: PMVC.U) (the “Company”) today announced that, commencing on November 12, 2020, holders of the units (the “Units”) sold in the Company’s initial public offering may elect to separately trade shares of the Company’s Class A common stock (the “Common Stock”) and warrants (the “Warrants”) included in the units.

The Common Stock and Warrants received from the separated Units will trade on the New York Stock Exchange (“NYSE”) under the symbols “PMVC” and “PMVC WS”, respectively. Units that are not separated will continue to trade on the NYSE under the “PMVC.U” ticker symbol. No fractional Warrants will be issued upon separation of the Units and only whole Warrants will trade. Holders of Units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the Units into Common Stock and Warrants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About PMV Consumer Acquisition Corp.

PMV Consumer Acquisition Corp. is a special purpose acquisition company organized for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. The Company’s efforts to identify a prospective target business will not be limited to any particular industry or geographic region, although the Company initially intends to focus on target businesses in the consumer industry with enterprise valuations in the range of $200 million to $3.5 billion.

Forward Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward-looking statements, including with respect to the initial public offering, the anticipated use of the proceeds thereof and the search for an initial business combination, are subject to risks and uncertainties, which could cause actual results to differ from the forward looking statements, including those set forth in the risk factors section of the prospectus used in connection with the Company’s initial public offering. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law.

Contact:

Peter D. Goldstein
Executive Vice President and Secretary
(561) 318-3766

nCino Announces Timing of its Third Quarter Fiscal 2021 Results Conference Call

WILMINGTON, N.C., Nov. 12, 2020 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO) will report financial results for its third quarter which ended October 31, 2020 after the market close on Wednesday, December 9, 2020. nCino will host a conference call and webcast that day at 4:30 p.m. ET to discuss its financial results.

What: nCino’s Third Quarter Fiscal Year 2021 Financial Results Conference Call
When: Wednesday, December 9, 2020 at 4:30 p.m. ET
Webcast Link: https://investor.ncino.com/ 

Replay: A webcast replay will be available on the Investor Relations section of nCino’s website following the call. 

About nCino

nCino (NASDAQ: NCNO) is the worldwide leader in cloud banking. The nCino Bank Operating System® empowers financial institutions with scalable technology to help them achieve revenue growth, greater efficiency, cost savings and regulatory compliance. In a digital-first world, nCino’s single digital platform enhances the employee and client experience to enable financial institutions to more effectively onboard new clients, make loans and manage the entire loan life cycle, and open deposit and other accounts across lines of business and channels. Transforming how financial institutions operate through innovation, reputation and speed, nCino works with more than 1,200 financial institutions globally, whose assets range in size from $30 million to more than $2 trillion. For more information, visit: www.ncino.com.

INVESTOR CONTACT

JoAnn Horne
Market Street Partners
+1 415.445.3240
[email protected] 

MEDIA CONTACT

Natalia Moose, nCino
+1 910.833.0970
[email protected] 

CB Scientific, Inc. (CBSC) Announces Definitive Agreement to Acquire Commercial Ambulatory ECG Device Manufacturer Datrix, LLC

Acquisition will expand Ambulatory Remote Cardiac ECG Monitoring product technology offering and outreach into US and international markets

ESCONDIDO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — via InvestorWire – CB Scientific. Inc. (OTC:CBSC) (“CBSC” or the “Company”), a provider of innovative products and services for the ambulatory noninvasive cardiac monitoring space, is pleased to announce a definitive purchase agreement to acquire Datrix, LLC (Datrix), a global ambulatory device manufacturer based in Escondido, California. Datrix brings to CBSC a diversely experienced team of highly qualified individuals with extensive knowledge of design and engineering related to medical devices utilized in this ever-expanding market. This acquisition further strengthens CBSC’s digital offering with the addition of an existing commercially available product line, which includes wireless mobile cardiac telemetry, cardiac event, extended and standard holter monitoring through the Datrix Sirona and VX3 devices.        

Under the terms of the acquisition agreement, Datrix will continue to operate as an OEM manufacturer to its existing customer base and also become the exclusive manufacturer for the next generation of CBSC’s proprietary FDA- and CE-cleared ECG my-Cam Cardiac Event Monitor, including the interactive cloud-based My-Cardia acquisition software and the associated smartphone apps. This acquisition also provides CBSC and its subsidiary My-Cardia (USA) Inc. the opportunity to expand their product offerings quickly with the addition, integration and implementation of Datrix’s wireless Sirona and VX3 devices. The addition of these new products to CBSC’s existing portfolio will now give the Company’s customers several new alternative monitoring/testing choices, which will further help improve earlier remote detection and diagnosis of problematic cardiac rhythms in patients. 

Jon Barron, president and founder of Datrix, LLC, said, “We are enthusiastic about our exciting new partnership with CBSC. They provide a great new platform for us to extend the outreach of our current products, improve and enhance their existing offerings, and expand the design and development of newer device technologies, leading to new avenues for improving the detection of cardiac heart rhythm abnormalities remotely.”

“We are extremely excited about our acquisition of Datrix, LLC and how it enhances and strengthens the growth trajectory of our business,” said Charles Martin, CBSC CEO. “The acquisition, combined with other expansion efforts already underway, will position CBSC to play a significant role in delivering innovative diagnostic devices and testing into this ever-expanding market, further helping our company to establish a solid footprint in the worldwide remote cardiac ambulatory noninvasive ECG monitoring market.”

The acquisition is expected to close during Q4 of fiscal year 2020, subject to customary closing conditions.  Financial terms of the agreement are not being disclosed.

As new developments occur, CB Scientific plans to make further announcements through press releases and regulatory filings to keep its shareholders, industry participants and the public markets informed.

About Datrix, LLC:

Datrix, LLC is a leading global manufacturer and provider of ambulatory ECG devices, established in 1988.  For over 30 years, medical companies, distributors and dealers have partnered with Datrix to design and develop dependable products with the latest technologies and advancements that meet the highest industry standard. Datrix’s approach to quality exceeds today’s requirements through the implementation of lean manufacturing practices. Their Quality Management System is certified to international standards of ISO 13485 and is in compliance with the Quality Systems Regulations of the FDA, with proprietary devices also bearing CE marking for conformity for marketing in the European Union. The manufacturing facility is registered with the FDA. For more information, please visit: www.datrixmed.com.

CB Scientific Inc. Company Contact Information:

340 State Place
Escondido, CA 92029
Telephone number:
(888) 225-0870

Emails:
General inquires: [email protected]
Investor Inquiries: [email protected]

Company Website and Social Media Outlets:
CB Scientificwebsite, Twitter, Facebook, Instagram and LinkedIn

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words plan,” “expect,” “believe” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements.  Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Wire Service Contact

InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
[email protected]

Translate Bio to Participate in Upcoming Investor Conferences

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) — Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that the Company will participate in the following upcoming investor conferences:

  • Jefferies Virtual London Healthcare Conference
    : John Schroer, chief financial officer, will present a corporate overview at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 7:55 a.m. ET.
  • Evercore ISI
    HealthCONx
    Conference
    : Ronald Renaud, chief executive officer, will participate in a fireside chat at the Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 at 2:15 p.m. ET.

A live webcast of the sessions will be accessible through the “Events and Presentations” page of the Company’s website at investors.translate.bio. A replay of the webcasts will be archived on the Translate Bio’s website for 30 days following the presentation.

About Translate Bio

Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases caused by insufficient protein production or where the reduction of proteins can modify disease. Translate Bio’s lead pulmonary candidate is being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio believes that mRNA can be delivered to target tissues via multiple routes of administration and, consequently, its technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.

Contacts for Translate Bio
   
Investors 
Teri Dahlman
[email protected]
617-817-8655
Media

Maura Gavaghan
[email protected]
617-233-1154

Revlon Announces Final Results and Expiration of Amended and Restated Exchange Offer and Concurrent Consent Solicitation

Revlon Announces Final Results and Expiration of Amended and Restated Exchange Offer and Concurrent Consent Solicitation

NEW YORK–(BUSINESS WIRE)–
Revlon, Inc. (NYSE: REV) announced today the final results and expiration of its previously-announced exchange offer and consent solicitation (the “Exchange Offer and Consent Solicitation”) by Revlon Consumer Products Corporation, its direct wholly-owned operating subsidiary (the “Company”) that was made pursuant to the amended and restated offering memorandum and consent solicitation statement (the “Offering Memorandum”), dated October 23, 2020. The Company had offered to exchange any and all its 5.75% Senior Notes due 2021 (the “Notes”) issued pursuant to that certain indenture, dated February 8, 2013 (as amended, supplemented, or modified), by and among the Company, the guarantor parties thereto and U.S. Bank, National Association, as trustee (the “Indenture”), for (i) the cash consideration or (ii) the Mixed Consideration, in each case as described in the Amended and Restated Offering Memorandum.

As of 11:59 p.m., New York City time, on Tuesday, November 10, 2020 (the “ Expiration Time”), approximately $236 million aggregate principal amount of the Notes (or approximately 68.8% of the aggregate outstanding principal amount of such series of Notes) had been validly tendered into the Exchange Offer and Consent Solicitation and not withdrawn.

The Company has determined that all conditions precedent to the consummation of the Exchange Offer and Consent Solicitation have been satisfied, and acceptance and settlement is expected to occur on Friday, November 13, 2020 (the “Settlement Date”), assuming that all conditions precedent continue to be satisfied as of that time. On the Settlement Date, the Company will enter into a supplemental indenture to the Indenture to adopt the Proposed Amendments (as defined in the Offering Memorandum) which would eliminate substantially all restrictive covenants and certain events of default provisions. As a result, the Company does not expect that any bankruptcy or insolvency proceeding will be necessary.

Once the Settlement Date occurs, the Company expects to give irrevocable notice under the Indenture that it will optionally redeem, on December 14, 2020, the remaining approximately $106.8 million aggregate principal amount of Notes not tendered into the Exchange Offer and Consent Solicitation at a price equal to 100% of their aggregate principal amount, together with interest accrued on such Notes to, but excluding, the date of redemption, in accordance with the terms of the Indenture. As a result of such notice and the irrevocable deposit of funds with the Indenture trustee sufficient to effect such redemption, the Notes and the Indenture will be considered discharged in full effective as of November 13, 2020.

Debra Perelman, Revlon’s President and Chief Executive Officer, stated: “We are pleased by the favorable response to the Exchange Offer, and we look forward to closing it on Friday. This represents an important step towards strengthening our capital structure and better positions us to focus on our future growth. While we still have challenges to face – namely the ongoing impact of the COVID-19 pandemic – we believe that we have the right strategy in place and will continue to execute against it.”

About Revlon

Revlon has developed a long-standing reputation as a color authority and beauty trendsetter in the world of color cosmetics and hair care. Since its breakthrough launch of the first opaque nail enamel in 1932, Revlon has provided consumers with high quality product innovation, performance and sophisticated glamour. In 2016, Revlon acquired the iconic Elizabeth Arden company and its portfolio of brands, including its leading designer, heritage and celebrity fragrances. Today, Revlon’s diversified portfolio of brands is sold in approximately 150 countries around the world in most retail distribution channels, including prestige, salon, mass, and online. Revlon is among the leading global beauty companies, with some of the world’s most iconic and desired brands and product offerings in color cosmetics, skin care, hair color, hair care and fragrances under brands such as Revlon, Revlon Professional, Elizabeth Arden, Almay, Mitchum, CND, American Crew, Creme of Nature, Cutex, Juicy Couture, Elizabeth Taylor, Britney Spears, Curve, John Varvatos, Christina Aguilera and AllSaints.

Forward-Looking Statements

Statements made in this press release, which are not historical facts, are forward-looking and are provided pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date they are made and the Company undertakes no obligation to publicly update any forward-looking statement, whether to reflect actual results of operations; changes in financial condition; changes in general U.S. or international economic or industry conditions and/or conditions in the Company’s reportable segments; changes in estimates, expectations or assumptions; or other circumstances, conditions, developments and/or events arising after the issuance of this press release, except for the Company’s ongoing obligations under the U.S. federal securities laws. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on preliminary or potentially inaccurate estimates and assumptions that could cause actual results to differ materially from those expected or implied by the estimated financial information. Such forward-looking statements include, among other things, the Company’s ability to consummate the Exchange Offer and Consent Solicitation and the Company’s expectations regarding future liquidity, cash flows, mandatory debt payments and other expenditures and its plans to continue to execute its business strategy. Actual results may differ materially from the Company’s forward-looking statements for a number of reasons, including as a result of the risks and other items described in Revlon’s filings with the SEC, including, without limitation, in Revlon’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and amendments thereto, if any, filed with the SEC during 2019 and 2020 (which may be viewed on the SEC’s website at http://www.sec.gov or on Revlon, Inc.’s website at http://www.revloninc.com). Factors other than those referred to above, such as continuing adverse impacts from the ongoing and prolonged COVID-19 pandemic, could also cause Revlon’s results to differ materially from expected results. Additionally, the business and financial materials and any other statement or disclosure on, or made available through, Revlon’s website or other websites referenced herein shall not be incorporated by reference into this press release.

Media:

Sloane & Company

Dan Zacchei / Joe Germani

[email protected] / [email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Cosmetics Retail

MEDIA:

Logo
Logo

Strongbridge Biopharma plc Announces Participation in Two Upcoming Investor Conferences

DUBLIN, Ireland and TREVOSE, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will participate in fireside chats at the Stifel and Jefferies 2020 Virtual Healthcare Conferences.

Details for the presentations are as follows:

The Company’s presentations will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.

About Strongbridge Biopharma

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Contacts:

Investor Relations

Solebury Trout
Mike Biega
+1 617-221-9660
[email protected]

Corporate
&
Media Relations

Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
[email protected]

Bioceres Crop Solutions Corp. ReportsFiscal First Quarter 2021 Financial and Operating Results

 Bioceres Crop Solutions Corp. ReportsFiscal First Quarter 2021 Financial and Operating Results

 Core business maintains strong momentum, with Comparable Revenues and Adjusted EBITDA increasing 8% and 30%, respectively

Company acquires full ownership in Verdeca JV, consolidating HB4® Soy economics and increasing go-to market flexibility

Concurrent acquisition of wheat intellectual property rights from Arcadia and recent regulatory approval of drought tolerant HB4 Wheat in Argentina significantly strengthen Bioceres’ ability to catalyze global wheat market

ROSARIO, Argentina–(BUSINESS WIRE)–Bioceres Crop Solutions Corp. (“Bioceres” or the “Company”) (NYSE American: BIOX), a fully-integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, announced today its unaudited consolidated financial results for the three-month period ended September 30, 2020. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (“YoY”), unless noted otherwise.

KEY BUSINESS DEVELOPMENTS

• Subsequent to quarter-end, Bioceres acquired from Arcadia Biosciences Inc. (“Arcadia”) earlier today the remaining ownership interest in Verdeca LLC (“Verdeca”), a joint venture launched in 2012 to develop second generation biotechnologies for soybean and to commercialize HB4 Soy globally. By assuming full ownership of Verdeca, the Company expects to accelerate the execution of its HB4 Soy strategy, in particular by expanding breeding and go-to market collaborations with partners in new and existing geographies. Complete ownership will also enable Bioceres to capture more of the underlying economic value of HB4 Soy on a per hectare basis. As part of the transaction, the Company will own Verdeca´s vetted soybean library of gene-edited materials for developing new quality and productivity traits, as well as exclusive rights to all Arcadia technologies applicable to this crop.

• Under the terms of the above-mentioned agreement, Bioceres has also been granted Latin American rights to Arcadia’s wheat traits and Good Wheat® brand. This platform of genome-edited materials includes wheat varieties with 65% less gluten, 10-times the dietary fiber, and oxidative stability (which extends the shelf life of whole flours and derived products), while being substantially equivalent in all other aspects to conventional wheat. Some of the rights acquired are subject to clearances by third parties.

• In consideration for the acquisition of Arcadia’s interest in Verdeca, the wheat rights discussed above, and other intellectual property assets, Bioceres is paying $20 million at closing, through a combination of $5 million in cash and $15 million in equity (1,875,000 Bioceres´ common shares priced at $8) that is subject to a six-month lock-up period. One-third of these shares are pledged in favor of Bioceres and will be released when the aforementioned third-party clearances to the licensed wheat rights have been granted. Post-closing, the Company will pay: i) $2 million subject to obtaining Chinese import clearance for HB4 Soy or achieving penetration of the HB4 Soy technology in a minimum number of hectares, and ii) payments equivalent to 6% of the net HB4 technology royalties realized by Verdeca, until a $10 million aggregate amount is met. The overall total consideration is $32 million, excluding $1 million in fees and transaction costs to be reimbursed to Arcadia post-closing and non-Verdeca related royalties.

• On October 8, 2020, Bioceres’ drought tolerant HB4 Wheat was commercially approved in Argentina, subject to import approval being granted in Brazil, Argentina’s main wheat trading partner. This approval is the first for HB4 Wheat anywhere in the world and marks an historical milestone in the biotechnology sphere for this crop.

FISCAL 1Q21 FINANCIAL & BUSINESS HIGHLIGHTS

• Total revenue increased 8% on a comparable basis to $42.2 million, with Adjusted EBITDA rising 30% to $10.5 million.

• Bioceres’ cash position rose more than five-fold through more efficient sources of capital versus the same period in fiscal year 2020, including $17 million raised through the August 2020 local public offering of Rizobacter bonds bearing zero percent interest.

• The Company’s Net debt-to-EBITDA ratio was 2.12x at quarter-end, compared to 2.15x in fiscal 1Q20.

• HB4 Wheat and HB4 Soy inventory ramp-up processes advance as discussed in Bioceres’ previous Earnings Report. A dry winter season hindered wheat production in Argentina, but was conducive to highlighting the full potential of HB4 drought tolerance as this crop’s harvest approaches in the southern hemisphere.

MANAGEMENT REVIEW

Commenting on the Company’s transaction with Arcadia,Mr.Federico Trucco, Chief Executive Officer of Bioceres, said, “My first relevant transaction as CEO of Bioceres back in 2011-12 was the agreement with Arcadia Biosciences for the constitution and financing of Verdeca LLC. At that time, Bioceres could barely pay the due diligence and legal costs associated to the transaction, HB4 was a technology promise, our ability to de-regulate a GMO event was disputable, and the overall investment required to transform this promise into a commercially approved product was estimated at over $100 million by industry experts. To be able to say that we have successfully overcome these initial difficulties and are today re-gaining full control not only on HB4 Soy but also on other very attractive earlier stage technologies and technology platforms within Verdeca’s portfolio, fills me with enormous pride. I would like to thank Arcadia for trusting us back in 2012 and for helping us advance Verdeca’s pipeline to its current state. We also take this opportunity to welcome Arcadia as a new shareholder of our company.”

Mr. Trucco added, “We are announcing this important transaction little over one month after Argentina’s regulatory clearance of HB4 Wheat, becoming the first company globally to have a commercially enabled path to market for a drought tolerance trait in this staple crop. Encouraged by this development, we are adding to our portfolio of wheat technologies Arcadia’s genome-edited varieties, especially designed to tackle major consumer health concerns. This expanded wheat portfolio will allow us to further leverage our investments in closed growing systems which, in addition to strong identity preservation and traceability capabilities, remain of paramount importance as we engage with growers and consumers for which our technologies are relevant.”

Mr. Enrique Lopez Lecube, Chief Financial Officer of Bioceres, said, “Our recent agreement with Arcadia together with the HB4 Wheat approval in Argentina, both significant achievements for Bioceres, were preceded by the growth momentum that we maintained going into the new fiscal year. Sales for the first fiscal quarter grew 8% year over year, while Adjusted EBITDA increased 30% despite a slow start to the growing season, due to limited rainfall. The resilience of our core business, along with our strong balance sheet and cash position, are a solid foundation for generating substantially higher levels of growth as we continue to make further headway with our HB4 strategy. By acquiring full ownership of Verdeca we are now in a position to capture significantly more of our core technology’s underlying economic value, ensuring that we maximize ROI as we further invest in ramping up our inventories and in accelerating our commercial efforts.”

Operational Metrics (Millions of hectares)

1Q20

1Q21

%Change

Adjuvants

10.0

13.8

38

%

Inoculants

5.7

4.1

-28

%

Packs

1.3

2.2

69

%

Table 2: Key Financial Metrics (Figures in millions of US dollars, unless otherwise noted)

 

As Reported

% Change

Revenue by Segment

1Q20

 

1Q21

 

Reported

Comparable¹

Crop Protection

18.0

 

21.6

 

21

%

11

%

Seed and Integrated Products

5.5

 

8.7

 

57

%

57

%

Crop Nutrition

12.8

 

12.0

 

(6

%)

(15

%)

Total Revenue

36.3

 

42.4

 

17

%

8

%

Gross Profit

15.9

 

19.2

 

21

%

13

%

Gross Margin

43.9

%

45.4

%

156 bps

203 bps

Adjusted EBITDA

8.1

 

10.5

 

30

%

 

Adjusted EBITDA Margin

22.4

%

24.9

%

246 bps

 

Cash & Cash Equivalents

5.5

 

59.6

 

446

%

 

Net Debt to LTM EBITDA

2.15x

2.12x

 

 1. Comparable excludes the impact of IAS29 as discussed in more detail on page 17.

For a full version of Bioceres Fiscal First Quarter 2021 Earnings Release, please visit: investors.biocerescrops.com/financials/results-center FISCAL FIRST QUARTER 2021 EARNINGS CONFERENCE CALL When: November 12, 2020

Time: 8:30 a.m. Eastern time

Who:

Mr. Federico Trucco, Chief Executive Officer

Mr. Enrique Lecube, Chief Financial Officer

Mr. Maximo Goya, Investor Relations Leader

Dial-in: (888) 869-118 (U.S. domestic); (706) 643-590 (International)

Conference ID: 6740967

Webcast: https://investors.biocerescrops.com/home/default.aspx

About Bioceres Crop Solutions Corp.

Bioceres Crop Solutions Corp. (NYSE American: BIOX) is a fully integrated provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. To do this, Bioceres’ solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The Company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation crop nutrition and protection solutions. Through its HB4® program, the Company is bringing digital solutions to support growers’ decisions and provide end-to-end traceability for production outputs. For more information, visit https://investors.biocerescrops.com

Forward-looking statements

This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial information and, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses by governments, clients and the Company, on our business, financial condition, liquidity position and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. These forward-looking statements include, but are not limited to, whether (i) the health and safety measures implemented to safeguard employees and assure business continuity will be successful, (ii) the uncertainty related to COVID-19 in the farming community will be short lived, and (iii) we will be able to coordinate efforts to ramp up inventories. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the Company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the Company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the Company’s ability to achieve its strategic goals, including the uncertainties relating to the impact of COVID-19 on the Company’s business, operations, liquidity and financial results and the other factors that are described in the sections entitled “Risk Factors” in the Company’s Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the Company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law.

Investor Relations

Maximo Goya, Investor Relations

+54-341-4861100

[email protected]

KEYWORDS: Argentina South America

INDUSTRY KEYWORDS: Agriculture Natural Resources Manufacturing Other Natural Resources Chemicals/Plastics

MEDIA:

Logo
Logo

Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress

Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobimetinib Combination

First-in-Class
RAS(ON) Inhibitor Programs
for Five Targets
in Lead Optimization

REDWOOD CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced its financial results for the third quarter and nine months ended September 30, 2020, and provided a corporate update.

“Revolution Medicines is a leader in developing innovative medicines and treatment strategies on behalf of patients with RAS-addicted tumors. We are advancing a growing portfolio consisting of both direct RAS(ON) Inhibitors and RAS Companion Inhibitors designed to enable combination approaches, including RMC-4630 targeting SHP2, RMC-5552 targeting mTORC1, and inhibitors of SOS1,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines.

“In our RAS Companion Inhibitor portfolio, we continue to make important strides with RMC-4630, our clinical stage inhibitor of SHP2.   We selected the recommended Phase 2 dose and schedule (RP2DS) for both our monotherapy trial (RMC-4630-01) and the RMC-4630/cobimetinib (Cotellic®) combination arm of the RMC-4630-02 clinical trial, and each trial will further evaluate the appropriate RP2DS in expansion cohorts of molecularly selected patients. As anticipated, we recently dosed a first patient in a new combination study of RMC-4630 with the third-generation EGFR inhibitor, osimertinib (Tagrisso®). We also entered into a new clinical collaboration with AstraZeneca to study RMC-4630 in combination with an emerging asset targeting KRASG12C from AstraZeneca’s portfolio.

“In addition, we accelerated growth of our RAS(ON) Inhibitor platform, which has produced a collection of potent, cell-active inhibitors of diverse oncogenic RAS variants responsible for the vast majority of RAS-addicted cancers.  Previously, we demonstrated significant anti-tumor effects of a representative potent and oral inhibitor of KRASG12C(ON). During the third quarter we confirmed the broad scope of our platform by demonstrating that representative KRASG12D(ON) inhibitors likewise induced tumor regressions in a preclinical model of human pancreatic cancer harboring the oncogenic KRASG12D mutation.   We have advanced our KRASG12C/NRASG12C(ON), KRASG12D(ON), KRASG13C(ON) and KRASG12V(ON) inhibitor programs into lead optimization.”  

R&D Highlights

RAS Companion Inhibitors

  • Determined
    Recommended
    Phase 2 Dose and Schedule
    (RP2DS)
    for single agent RMC-
    4630
    Completed dose escalation and selected 200 mg administered on a Day 1/Day 2 (D1D2) weekly schedule as the RP2DS. The company plans to evaluate single agent RMC-4630 at the RP2DS in an expansion cohort of patients with gynecologic tumors harboring NF1LOF mutations, in addition to a small safety/tolerability cohort representing a broader set of histotypes and RAS pathway genotypes.

  • Determined RP2DS for RMC-4630 in
    C
    ombination with the MEK Inhibitor, Cobimetinib
    Completed dose escalation and selected RMC-4630 140 mg and cobimetinib 40 mg administered on a Day 1/Day 2 (D1D2) weekly schedule as the RP2DS. The company plans to further evaluate this combination at the RP2DS in expansion cohorts of patients with colorectal cancer harboring KRASG12V or KRASG12D mutations and others drawing from a broader set of histotypes and RAS pathway genotypes.

  • Interim Data Presented at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib
    Interim data reported by investigators support a dual intermittent dosing strategy for RMC-4630 and cobimetinib that appears tolerable and exceeds target plasma exposures for each drug based on preclinical models of RAS pathway-driven cancers that project potential clinical activity. Investigators also reported preliminary evidence of anti-tumor activity in patients with colorectal cancer driven by KRAS mutations.

  • RMC-4630
    M
    ulti-
    C
    ohort Phase 1/2
    C
    linical
    P
    rogram
    E
    xpanding as
    P
    otential
    B
    ackbone for
    C
    ombination
    T
    herapies

    • Dosing and enrollment continue in the Amgen-sponsored Phase 1 study of RMC-4630 in combination with Amgen’s KRASG12C(OFF) inhibitor, AMG 510, or sotorasib
    • Dosing and enrollment continue in the Sanofi-sponsored Phase 1 study of RMC-4630 in combination with the PD-1 inhibitor, pembrozilumab (Keytruda®
    • Initiated a study evaluating RMC-4630 in combination with the EGFR inhibitor, osimertinib (Tagrisso®)
    • Entered into a new clinical collaboration agreement with AstraZeneca to study RMC-4630 in combination with an emerging asset targeting KRASG12C from AstraZeneca’s portfolio
  • Clinical Results
    Support
    Du
    a
    l
    Mechanisms
    of Anti-Tumor Activity
    by RMC-4630
    :
    Tumor Cell-Intrinsic
    and Stimulati
    on of
    Immune Response
     Data reported by the company from its ongoing RMC-4630-01 trial provide clinical evidence that SHP2 inhibition may act by stimulating arms of the immune system as a second anti-tumor mechanism in addition to its tumor cell-intrinsic benefits. These observations provide further rationale for the ongoing clinical combination study with RMC-4630 and pembrozilumab by Sanofi, the company’s SHP2 collaboration partner.

RAS(ON) Inhibitors

  • First-In-Class RAS(ON) Inhibitor Platform – The company’s proprietary tri-complex technology platform enables a highly differentiated approach to inhibiting RAS(ON) with potential biologic advantages. Revolution Medicines is developing a portfolio of compounds that it believes are the first and only RAS(ON) inhibitors to use this mechanism of action. The company has produced potent, cell-active RAS(ON) Inhibitors for variants driving the vast majority of RAS-addicted cancers.

  • Inhibitors for Five RAS(ON) Variants in Lead Optimization – KRASG12C/NRASG12C(ON), KRASG12D(ON), KRASG13C(ON), and KRASG12V(ON) inhibitors are in lead optimization, which include and expands on the company’s initial four priority RAS(ON) targets. The company remains on track to nominate a first development candidate from this platform by the end of 2020.

  • Preclinical Tumor Regressions Induced by First-in-Class KRAS

    G12D

    (ON) Inhibitors
    Data presented by the company at the RAS Targeted Drug Development conference demonstrated that the company’s first-in-class KRASG12D(ON) inhibitors induced significant decreases in tumor volume in a xenograft model of human pancreatic cancer driven by a KRASG12D mutation. The KRASG12D genotype is of particularly high clinical interest as there are currently no approved targeted therapies for the treatment of cancers driven by this mutation, which is found in approximately 35% of pancreatic cancers and 15% of colorectal cancers in the U.S.

Corporate Highlights

  • Completed Follow-On Financing  The company completed a follow-on equity public offering in July 2020.  The upsized financing raised gross proceeds of $179.4 million before deducting underwriting discounts, commissions and other offering expenses payable by Revolution Medicines, further strengthening its balance sheet to support multiple clinical milestones and extend the company’s runway.

Upcoming Corporate Milestones

RAS(ON) Inhibitors

  • Nominate first development candidate (Q4 2020)
  • Nominate second development candidate (1H 2021)

RAS Companion Inhibitors

  • SHP2 (RMC-4630)

    • Report monotherapy dose escalation safety data set (1H 2021)
    • Provide preliminary activity data for combination with cobimetinib (2H 2021)
    • Provide initial tolerability and PK data for combination with osimertinib (2H 2021)
  • mTORC1/4EBP1 (RMC-5552)

    • Advance to IND-ready status (Q4 2020)
    • Begin treating patients with monotherapy (1H 2021)

Third Quarter 2020 Financial Highlights

Cash Position: Cash, cash equivalents and marketable securities were $466.1 million as of September 30, 2020, compared to $122.8 million as of December 31, 2019. The increase was primarily due to proceeds from the company’s initial public offering in February 2020 and follow-on equity public offering in July 2020.

Revenue: Total revenue, consisting of revenue from the company’s collaboration agreement with Sanofi, was $12.7 million for the quarter ended September 30, 2020, compared to $12.5 million for the quarter ended September 30, 2019.

R&D Expenses: Research and development expenses were $34.9 million for the quarter ended September 30, 2020, compared to $23.0 million for the quarter ended September 30, 2019. This increase was primarily due to an increase in research expenses associated with the company’s pre-clinical research portfolio, and an increase in personnel-related expenses related to additional headcount.

G&A Expenses: General and administrative expenses were $5.3 million for the quarter ended September 30, 2020, compared to $3.1 million for the quarter ended September 30, 2019. This increase was primarily due to an increase in expenses associated with operating as a public company.

Net Loss: Net loss was $27.2 million for the quarter ended September 30, 2020, compared to net loss of $12.8 million for the quarter ended September 30, 2019.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors include compounds targeting KRASG12C/NRASG12C(ON), KRASG12D(ON), KRASG13C(ON), KRASG12V(ON) and other RAS variants. RAS Companion Inhibitors include RMC-4630 targeting SHP2, RMC-5552 targeting mTORC1, and inhibitors of SOS1.

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.   Tagrisso® is a registered trademark of the AstraZeneca group of companies.  Cotellic® is the registered trademark of Genentech, Inc. (a member of the Roche Group).


Forward Looking Statements

This press release contains forward-looking statements within the meaning of
the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding Revolution Medicines’ development plans and timelines and its ability to advance its portfolio and R&D pipeline; enrollment in the company’s clinical trials and the tolerability and potential efficacy of the company’s candidates being studied; the ability of
the company’s
therapies to inhibit frontier targets in RAS-addicted cancers; the company’s planned expansion cohorts for single-agent RMC-4630 and RMC-4630 in combination with cobimetinib; the growth and scope of
the company’s
RAS(ON) Inhibitor platform; the potential advantages and effectiveness of the company’s preclinical candidates, including its RAS(ON)
I
nhibitors;
the company’s
plan
s
to nominate development candidate
s
from its family of RAS(ON)
Inhibitors; the company’s plans to release data related to its RAS Companion Inhibitors;
the company’s
plan to advance RMC-5552 to IND-ready status and to begin treating patients with RMC-5552 monotherapy.
Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including
the company’s
programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products,
the company’s
ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of
the company’s
capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape
and the effects on our business of the worldwide COVID-19 pandemic
.
For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2020, and its future periodic reports to be filed with the Securities and Exchange Commission
. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

R
EVOLUTION MEDICINES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

(unaudited)

    Three Months Ended

September 30,
    Nine Months Ended

September 30,
 
    2020     2019     2020     2019  
Revenue:                                
Collaboration revenue, related party   $ 12,661     $ 12,506     $ 34,232     $ 37,953  
Total revenue     12,661       12,506       34,232       37,953  
Operating expenses:                                
Research and development     34,871       22,962       95,246       64,265  
General and administrative     5,341       3,103       15,603       8,244  
Total operating expenses     40,212       26,065       110,849       72,509  
Loss from operations     (27,551 )     (13,559 )     (76,617 )     (34,556 )
Other income, net:                                
Interest income     347       766       1,986       1,571  
Interest and other expense     (17 )     (25 )     (57 )     (83 )
Total other income, net     330       741       1,929       1,488  
Loss before income taxes     (27,221 )     (12,818 )     (74,688 )     (33,068 )
Benefit from income taxes                 733        
Net loss   $ (27,221 )   $ (12,818 )   $ (73,955 )   $ (33,068 )
Redeemable convertible preferred stock dividends – undeclared and cumulative           (4,247 )     (2,219 )     (9,987 )
Net loss attributable to common stockholders   $ (27,221 )   $ (17,065 )   $ (76,174 )   $ (43,055 )
Net loss per share attributable to common stockholders – basic and diluted   $ (0.42 )   $ (6.08 )   $ (1.49 )   $ (15.81 )
Weighted-average common shares used to compute net loss per share, basic and diluted     64,892,868       2,806,470       51,031,003       2,723,541  



REVOLUTION MEDICINES, INC.

SELECTED CONDENSED CONSOLIDATED B
ALANCE SHEETS

(in thousands, unaudited)

    September
30,
    December 31,  
    2020     2019  
                 
Cash, cash equivalents and marketable securities   $ 466,140     $ 122,758  
Working capital (1)     440,514       90,929  
Total assets     595,070       220,529  
Deferred revenue     22,882       31,851  
Total liabilities     90,000       67,994  
Redeemable convertible preferred stock           305,109  
Total stockholders’ equity (deficit)     505,070       (152,574 )

      (1)   Working capital is defined as current assets less current liabilities.

Contacts: 
For Investors: 
Vida Strategic Partners 
Stephanie Diaz 
415-675-7401 
[email protected]

For Media: 
Vida Strategic Partners 
Tim Brons 
415-675-7402 
[email protected]

Limbach Holdings Reports Third Quarter 2020 Results

Limbach Holdings Reports Third Quarter 2020 Results

Third Quarter 2020 Revenue Increases 10.6% over prior year; Diluted EPS of $0.31; Third Quarter Net Cash Provided by Operating Activities of $12.8 million

Increasing Adjusted EBITDA Guidance for Fiscal 2020

Conference Call Scheduled for 10:00 am ET on November 12, 2020

PITTSBURGH–(BUSINESS WIRE)–
Limbach Holdings, Inc. (Nasdaq: LMB) (“Limbach” or the “Company”) today announced its financial results for the quarter ended September 30, 2020. Revenue for the third quarter increased 10.6% from the prior year period to $163.9 million. Gross margin in the quarter was 14.8%, an increase of 235 basis points as compared to the same period during fiscal year 2019. Greater gross profit combined with moderate growth in selling, general and administrative expenses resulted in net income of $2.5 million and Adjusted EBITDA of $8.8 million which reflects Adjusted EBITDA growth of more than twice the prior year period amount. The Company generated strong cash flow, with net cash provided by operating activities of $12.8 million in the quarter.

The following are key financial highlights of the third quarter. All comparisons are to the third quarter of 2019, unless noted otherwise.

  • Construction segment revenue of $130.5 million increased 10.2% driven by growth in the Michigan, Ohio, and New England operating regions, offset by revenue declines in the Florida, Southern California and Eastern Pennsylvania regions. Service segment revenue of $33.4 million increased 12.3%, driven by growth in the Florida, Mid-Atlantic and Western Pennsylvania regions, offset by a revenue decline in the Michigan region.
  • Gross margin increased to 14.8% from 12.4%, primarily as a result of improved project execution in the Construction segment and improved pricing and business mix in the Service segment. Gross margin in the Service segment was 27.9% representing an increase of 360 basis points.
  • SG&A expense in the third quarter increased approximately $0.4 million to $17.0 million as compared to $16.6 million as the Company continued to invest in Service segment and owner-direct sales and execution resources. That growth in SG&A expense was offset by a decline in Construction segment and Corporate SG&A which reflects the continuing effort to identify cost reductions undertaken earlier in the calendar year. As a percent of revenue, SG&A expense was 10.4% as compared to 11.2%.
  • Interest expense was $2.2 million in the third quarter of 2020 as compared to $1.8 million as the Company paid higher interest rates under the Company’s term loan following the execution in the third quarter of 2019 of an amendment to its credit facility.
  • Net income in the third quarter was $2.5 million compared with a net loss of $(3.0) million. Diluted EPS increased to $0.31 as compared to $(0.39).
  • Net cash provided by operating activities was $12.8 million in the third quarter, as compared to net cash used in operating activities of $(1.9) million.
  • Total backlog at September 30, 2020 was $469.3 million as compared to $470.6 million as of June 30, 2020 and $561.2 million as of December 31, 2019. At September 30, 2020, Construction segment backlog accounted for $407.5 million of the consolidated total. Service segment backlog accounted for $61.8 million of the consolidated total.

Charlie Bacon, Limbach’s President and Chief Executive Officer, said, “Overall, we experienced a more normalized operating environment during the third quarter. Our strong performance on a consolidated basis reflected continuing improvement in execution in the Construction segment. We expect that dynamic to continue over the coming quarters as older, lower-margin projects are completed and are replaced with higher margin opportunities that better reflect our enhanced risk management paradigm. We’re pleased with the quality and quantity of the mid-size and large project opportunities we are negotiating and booking into backlog and remain disciplined about project selection. We also generated sequential growth in the Service segment where the impact from COVID-19 had been most significant earlier this year. The velocity we experienced in the Service segment this quarter better reflects what we consider to be a run-rate level of activity, and we’re obviously pleased with the continued expansion in margins.”

Mr. Bacon continued, “We also saw another quarter of cash flow generation and improvement in working capital and liquidity. Our quarter-end cash balance increased 37.4% sequentially to $39.6 million, and we again finished the quarter undrawn on the revolver other than to support certain standby letters of credit. Strengthening the balance sheet has been a core initiative all year and will remain so as we enter the winter season and prepare to confront a number of economic, political and public-health uncertainties. Despite these continued distractions, our employees persevered to generate solid financial and operating performance during the quarter and remain well focused on working safely. Given our performance on a year-to-date basis, we are increasing our Adjusted EBITDA guidance from a range of $22-24 million to a range of $23-26 million. We’re maintaining revenue guidance of $560-600 million. We’re excited to carry this momentum through the balance of the year and into 2021.”

Third Quarter 2020 Summary

Revenue

Third quarter 2020 revenue increased 10.6% to $163.9 million compared to $148.1 million in the prior year period. Revenue for the third quarter of 2019 is “As Recast” to reflect the adoption of ASC Topic 606, which amends the existing accounting standards for revenue recognition and establishes principles for recognizing revenue upon the transfer of promised goods or services to customers based on the expected consideration to be received in exchange for those goods or services.

Construction segment of $130.5 million increased 10.2% driven by growth in the Michigan, Ohio and New England operating regions mainly as a result of the start of new projects and the continuation of work on existing projects. These increases were partially offset by revenue decreases in the Florida operating region largely due to project shutdowns due to COVID-19, planned reductions in revenue in the Southern California region and a decrease in revenue in the Eastern Pennsylvania region due to the substantial completion of projects in the third quarter of 2020 compared to the same prior year quarter. Service segment revenue of $33.4 million represented an increase of 12.3% over the third quarter of 2019, driven by growth in the Florida, Mid-Atlantic and Western Pennsylvania regions, offset by a revenue decline in the Michigan region.

Gross Profit

Total gross margin for the quarter was 14.8% as compared to 12.4% in last year’s third quarter. Gross profit for the third quarter of 2019 is “As Recast” to reflect the adoption of ASC Topic 606. In the current period, gross profit in the Construction segment increased by 33.2% driven by higher margins and a reduction in project write-downs. Gross profit in the Service segment increased by 29.0% as a result of more favorable project pricing across most lines of business which remains a key focus area.

Gross profit was negatively impacted by the recognition of net project write-downs of $2.4 million, approximately two-thirds of which are related to previously addressed projects in the Southern California region. That net project adjustment was more favorable than the net project adjustment recognized in the prior year period which also included write-downs on several projects in the Southern California operating region.

SG&A Expense

SG&A expense for the third quarter was $17.0 million compared to $16.6 million in the prior year period. The increase of approximately $0.4 million resulted from an increase of $2.1 million in higher performance-based compensation expense due to the Company’s current year-to-date performance, offset by expense reductions in payroll, travel and entertainment, and other Corporate categories. As a percent of total revenue, SG&A expense for the third quarter declined to 10.4% from 11.2% in the prior year period.

Net Income

Net income was $2.5 million compared to a net loss of $(3.0) million in the prior year period. Net loss for the third quarter of 2019 is “As Recast” to reflect the adoption of ASC Topic 606. Net income per basic and diluted share for the third quarter was $0.32 and $0.31, respectively, compared to a net loss per share of $(0.39) for both basic and diluted for the prior year period.

Adjusted EBITDA

Adjusted EBITDA for the third quarter was $8.8 million as compared to $3.8 million in the prior year period, an increase of 130.4%. Adjusted EBITDA for the third quarter of 2019 is “As Recast” to reflect the adoption of ASC Topic 606. The increase in Adjusted EBITDA was primarily attributable to the increased revenue and gross margins in both the Construction and Service segments during the third quarter of 2020, offset by a moderate increase in SG&A expense.

Backlog and Remaining Performance Obligations

Total backlog at September 30, 2020 was $469.3 million as compared to $561.2 million as of December 31, 2019. At September 30, 2020, Construction segment backlog accounted for $407.5 million of the consolidated total, a decrease of 19.2% as compared to Construction segment backlog at December 31, 2019 of $504.2 million. Service segment backlog accounted for $61.8 million of the consolidated total, an increase of 8.4% as compared to Service segment backlog of $57.0 million at December 31, 2019.

Backlog includes unexercised contract options which are not included in the Company’s remaining performance obligations. At September 30, 2020, remaining performance obligations of the Company’s Construction and Service segment contracts were $407.5 million and $47.6 million, respectively. At December 31, 2019, remaining performance obligations of the Company’s Construction and Service segment contracts were $504.2 million and $41.9 million, respectively.

Balance Sheet

At September 30, 2020, the Company had current assets of $237.7 million and current liabilities of $187.0 million, representing a current ratio of 1.27x. Working capital was $50.7 million at September 30, 2020, an increase of $12.2 million from December 31, 2019. The Company had no borrowings against its $14.0 million revolving credit facility at September 30, 2020, other than for standby letters of credit totaling $3.4 million.

2020 Guidance

The Company announces the following updated guidance for 2020:

 

 

Current

Previous

Revenue

$560 million – $600 million

$560 million – $600 million

Adjusted EBITDA

$23 million – $26 million

$22 million – $24 million

In addition to the risks and uncertainties identified under “Forward-Looking Statements,” the Company’s 2020 guidance is estimated based on the assumption that any impact on the Company in the fourth quarter of the year from a resurgence of COVID-19 is no more extensive or impactful than what Limbach and the construction industry in the United States experienced in the third quarter of fiscal year 2020.

With respect to projected fiscal year 2020 Adjusted EBITDA, a quantitative reconciliation is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to taxes and other items, which are excluded from Adjusted EBITDA. We expect the variability of this item to have a potentially unpredictable, and potentially significant, impact on our future financial results.

 

Conference Call Details

 

 

Date:

Thursday, November 12, 2020

 

Time:

10:00 a.m. Eastern Time

 

Participant Dial-In Numbers:

 

Domestic callers:

(866) 604-1698

International callers:

(201) 389-0844

Access by Webcast

The call will also be simultaneously webcast over the Internet via the “Investor Relations” section of LMB’s website at www.limbachinc.com or by clicking on the conference call link: https://78449.themediaframe.com/dataconf/productusers/lmb/mediaframe/41132/indexl.html. An audio replay of the call will be archived on the Company’s website for 365 days.

About Limbach

Founded in 1901, Limbach is the 8th largest mechanical systems solutions firm and 44th largest specialty contractor in the United States as determined by Engineering News Record. Limbach provides building infrastructure services, with an expertise in the design, installation and maintenance of HVAC and mechanical, electrical, and plumbing systems for a diversified group of commercial and institutional building owners. Limbach employs more than 1,700 employees in 22 offices throughout the United States. The Company’s full life-cycle capabilities, from concept design and engineering through system commissioning and recurring 24/7 service and maintenance, position Limbach as a value-added and essential partner for building owners, construction managers, general contractors and energy service companies.

Recast Presentation for 2019

As noted, Revenue for the third quarter of 2019 is “As Recast” to reflect the adoption of ASC Topic 606, which amends the existing accounting standards for revenue recognition and establishes principles for recognizing revenue upon the transfer of promised goods or services to customers based on the expected consideration to be received in exchange for those goods or services. For more information, including reconciliation related to the As Recast Revenue numbers, please refer to our periodic filings, which are available on the SEC’s website (www.sec.gov).

Forward-Looking Statements

We make forward-looking statements in this press release within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events, including, without limitation, our earnings, adjusted EBITDA, revenues, expenses, backlog, capital expenditures or other future financial or business performance or strategies, results of operations or financial condition, and in particular statements regarding the impact of the COVID-19 pandemic on the construction industry in the fourth quarter and future periods, timing of the recognition of backlog as revenue, the potential for recovery of cost overruns, and the ability of the Company to successfully remedy the issues that have led to write-downs in various business units. These statements may be preceded by, followed by or include the words “may,” “might,” “will,” “will likely result,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or similar expressions. These forward-looking statements are based on information available to us as of the date they were made and involve a number of risks and uncertainties which may cause them to turn out to be wrong. Some of these risks and uncertainties may in the future be amplified by the COVID-19 outbreak and there may be additional risks that we consider immaterial or which are unknown. Additionally, our revised “2020 Guidance” is inherently forward looking, and is subject to a number of risks and uncertainties and assumptions which may ultimately cause that guidance to be different than we project. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Please refer to our most recent annual report on Form 10-K, as well as our subsequent filings on Form 10-Q and Form 8-K, which are available on the SEC’s website (www.sec.gov), for a full discussion of the risks and other factors that may impact any forward-looking statements in this press release.

 

LIMBACH HOLDINGS, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

 

 

Three months ended

September 30,

 

Nine months ended

September 30,

 

 

2020

 

2019

 

2020

 

2019

(in thousands, except share and per share data)

 

 

 

(As Recast)

 

 

 

(As Recast)

Revenue

 

$

163,856

 

 

 

$

148,119

 

 

 

$

437,813

 

 

 

$

414,469

 

 

Cost of revenue

 

139,685

 

 

 

129,746

 

 

 

375,083

 

 

 

358,778

 

 

Gross profit

 

24,171

 

 

 

18,373

 

 

 

62,730

 

 

 

55,691

 

 

Operating expenses:

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

17,045

 

 

 

16,568

 

 

 

47,596

 

 

 

49,691

 

 

Amortization of intangibles

 

109

 

 

 

149

 

 

 

526

 

 

 

499

 

 

Total operating expenses

 

17,154

 

 

 

16,717

 

 

 

48,122

 

 

 

50,190

 

 

Operating income

 

7,017

 

 

 

1,656

 

 

 

14,608

 

 

 

5,501

 

 

Other income (expenses):

 

 

 

 

 

 

 

 

Interest expense, net

 

(2,154

)

 

 

(1,759

)

 

 

(6,449

)

 

 

(4,190

)

 

Gain on disposition of property and equipment

 

3

 

 

 

17

 

 

 

18

 

 

 

38

 

 

Loss on debt extinguishment

 

 

 

 

 

 

 

 

 

 

(513

)

 

Gain (loss) on change in fair value of warrant liability

 

(1,371

)

 

 

525

 

 

 

(1,312

)

 

 

422

 

 

Impairment of goodwill

 

 

 

 

(4,359

)

 

 

 

 

 

(4,359

)

 

Total other expenses

 

(3,522

)

 

 

(5,576

)

 

 

(7,743

)

 

 

(8,602

)

 

Income (loss) before income taxes

 

3,495

 

 

 

(3,920

)

 

 

6,865

 

 

 

(3,101

)

 

Income tax provision (benefit)

 

970

 

 

 

(942

)

 

 

1,445

 

 

 

(681

)

 

Net income (loss)

 

$

2,525

 

 

 

$

(2,978

)

 

 

$

5,420

 

 

 

$

(2,420

)

 

Earnings Per Share (“EPS”)

 

 

 

 

 

 

 

 

Income (loss) per common share:

 

 

 

 

 

 

 

 

Basic

 

$

0.32

 

 

 

$

(0.39

)

 

 

$

0.69

 

 

 

$

(0.32

)

 

Diluted

 

$

0.31

 

 

 

$

(0.39

)

 

 

$

0.68

 

 

 

$

(0.32

)

 

Weighted average number of shares outstanding:

 

 

 

 

 

 

 

 

Basic

 

7,890,074

 

 

 

7,673,517

 

 

 

7,844,587

 

 

 

7,653,372

 

 

Diluted

 

8,107,149

 

 

 

7,673,517

 

 

 

7,969,857

 

 

 

7,653,372

 

 

LIMBACH HOLDINGS, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

September 30,

 

December 31,

(in thousands, except share and per share data)

2020

2019

ASSETS

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

39,600

 

 

 

$

8,344

 

 

Restricted cash

113

 

 

 

113

 

 

Accounts receivable, net

124,839

 

 

 

105,067

 

 

Contract assets

68,576

 

 

 

77,188

 

 

Income tax receivable

685

 

 

 

494

 

 

Other current assets

3,908

 

 

 

4,174

 

 

Total current assets

237,721

 

 

 

195,380

 

 

 

 

 

 

Property and equipment, net

20,582

 

 

 

21,287

 

 

Intangible assets, net

11,785

 

 

 

12,311

 

 

Goodwill

6,129

 

 

 

6,129

 

 

Operating lease right-of-use assets

19,533

 

 

 

21,056

 

 

Deferred tax asset

4,575

 

 

 

4,786

 

 

Other assets

461

 

 

 

668

 

 

Total assets

$

300,786

 

 

 

$

261,617

 

 

 

 

 

 

LIABILITIES

 

 

 

Current liabilities

 

 

 

Current portion of long-term debt

$

6,612

 

 

 

$

4,425

 

 

Current operating lease liabilities

3,875

 

 

 

3,750

 

 

Accounts payable, including retainage

88,962

 

 

 

86,267

 

 

Contract liabilities

61,085

 

 

 

42,370

 

 

Accrued income taxes

1,959

 

 

 

12

 

 

Accrued expenses and other current liabilities

24,508

 

 

 

20,045

 

 

Total current liabilities

187,001

 

 

 

156,869

 

 

Long-term debt

37,462

 

 

 

38,868

 

 

Long-term operating lease liabilities

16,402

 

 

 

18,247

 

 

Other long-term liabilities

6,794

 

 

 

763

 

 

Total liabilities

247,659

 

 

 

214,747

 

 

Commitments and contingencies

 

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY

 

 

 

Common stock, $0.0001 par value; 100,000,000 shares authorized, 7,894,202 issued and outstanding at September 30, 2020 and 7,688,958 at December 31, 2019

1

 

 

 

1

 

 

Additional paid-in capital

57,394

 

 

 

56,557

 

 

Accumulated deficit

(4,268

)

 

 

(9,688

)

 

Total stockholders’ equity

53,127

 

 

 

46,870

 

 

Total liabilities and stockholders’ equity

$

300,786

 

 

 

$

261,617

 

 

 

LIMBACH HOLDINGS, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

Nine months ended

September 30,

 

2020

 

2019

(in thousands)

 

 

(As Recast)

Cash flows from operating activities:

 

 

 

Net income (loss)

$

5,420

 

 

 

$

(2,420

)

 

Adjustments to reconcile net income to cash provided by (used in) operating activities:

 

 

 

Depreciation and amortization

4,635

 

 

 

4,234

 

 

Impairment of goodwill

 

 

 

4,359

 

 

Provision for doubtful accounts

62

 

 

 

104

 

 

Stock-based compensation expense

739

 

 

 

1,373

 

 

Noncash operating lease expense

3,033

 

 

 

2,789

 

 

Amortization of debt issuance costs

1,620

 

 

 

901

 

 

Deferred income tax (benefit) provision

211

 

 

 

(775

)

 

Gain on sale of property and equipment

(18

)

 

 

(38

)

 

Loss on debt extinguishment

 

 

 

513

 

 

Gain on change in fair value of warrant liability

1,312

 

 

 

(422

)

 

Changes in operating assets and liabilities:

 

 

 

Accounts receivable

(19,834

)

 

 

(5,223

)

 

Contract assets

8,612

 

 

 

(15,768

)

 

Other current assets

270

 

 

 

29,733

 

 

Accounts payable, including retainage

2,695

 

 

 

(1,406

)

 

Prepaid income taxes

(192

)

 

 

77

 

 

Accrued taxes payable

1,947

 

 

 

63

 

 

Contract liabilities

18,715

 

 

 

(6,826

)

 

Operating lease liabilities

(3,229

)

 

 

(2,789

)

 

Accrued expenses and other current liabilities

8,925

 

 

 

(25,961

)

 

Other long-term liabilities

306

 

 

 

(102

)

 

Net cash provided by (used in) operating activities

35,229

 

 

 

(17,584

)

 

Cash flows from investing activities:

 

 

 

Proceeds from sale of property and equipment

65

 

 

 

148

 

 

Advances (to) from joint ventures

(3

)

 

 

3

 

 

Purchase of property and equipment

(1,116

)

 

 

(2,192

)

 

Net cash used in investing activities

(1,054

)

 

 

(2,041

)

 

Cash flows from financing activities:

 

 

 

Increase in bank overdrafts

 

 

 

6,102

 

 

Payments on Credit Agreement term loan

 

 

 

(14,335

)

 

Proceeds from Credit Agreement revolver

 

 

 

17,500

 

 

Payments on Credit Agreement revolver

 

 

 

(17,500

)

 

Proceeds from 2019 Revolving Credit Facility

7,250

 

 

 

19,250

 

 

Payments on 2019 Revolving Credit Facility

(7,250

)

 

 

(19,250

)

 

Payments on 2019 Refinancing Term Loan

(1,000

)

 

 

 

 

Proceeds from 2019 refinancing Term Loan, net of debt discount

 

 

 

38,643

 

 

Warrants issued in conjunction with the 2019 Refinancing Term Loan

 

 

 

969

 

 

Embedded derivative associated with the 2019 Refinancing Term Loan

 

 

 

388

 

 

Payments on Bridge Term Loan

 

 

 

(7,736

)

 

Payments on finance leases

(1,966

)

 

 

(1,803

)

 

Payments of debt issuance costs

 

 

 

(3,339

)

 

Taxes paid related to net-share settlement of equity awards

(102

)

 

 

(123

)

 

Proceeds from contributions to Employee Stock Purchase Plan

149

 

 

 

 

 

Net cash (used in) provided by financing activities

(2,919

)

 

 

18,766

 

 

Increase in cash, cash equivalents and restricted cash

31,256

 

 

 

(859

)

 

Cash, cash equivalents and restricted cash, beginning of period

8,457

 

 

 

1,732

 

 

Cash, cash equivalents and restricted cash, end of period

$

39,713

 

 

 

$

873

 

 

Supplemental disclosures of cash flow information

 

 

 

Noncash investing and financing transactions:

 

 

 

Right of use assets obtained in exchange for new operating lease liabilities

$

924

 

 

 

$

3,022

 

 

Right of use assets obtained in exchange for new finance lease liabilities

2,399

 

 

 

2,685

 

 

Right of use assets disposed or adjusted modifying operating lease liabilities

586

 

 

 

1,651

 

 

Right of use assets disposed or adjusted modifying finance lease liabilities

(64

)

 

 

(55

)

 

Interest paid

$

4,817

 

 

 

$

3,091

 

 

LIMBACH HOLDINGS, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

 

Three months ended

September 30,

Increase/(Decrease)

 

2020

 

2019

 

 

 

(in thousands)

 

 

(As Recast)

$

 

%

Statement of Operations Data:

 

 

 

 

 

 

Revenue:

 

 

 

 

 

 

Construction

$

130,498

 

 

 

$

118,424

 

 

$

12,074

 

 

 

10.2

 

%

Service

33,358

 

 

 

29,695

 

 

3,663

 

 

 

12.3

 

%

Total revenue

163,856

 

 

 

148,119

 

 

15,737

 

 

 

10.6

 

%

 

 

 

 

 

 

 

Gross profit:

 

 

 

 

 

 

Construction

14,848

 

 

 

11,144

 

 

3,704

 

 

 

33.2

 

%

Service

9,323

 

 

 

7,229

 

 

2,094

 

 

 

29.0

 

%

Total gross profit

24,171

 

 

 

18,373

 

 

5,798

 

 

 

31.6

 

%

 

 

 

 

 

 

 

Selling, general and administrative expenses:(1)

 

 

 

 

 

 

Construction

10,501

 

 

 

10,746

 

 

(245

)

 

 

(2.3

)

%

Service

6,240

 

 

 

5,329

 

 

911

 

 

 

17.1

 

%

Corporate

304

 

 

 

493

 

 

(189

)

 

 

(38.3

)

%

Total selling, general and administrative expenses

17,045

 

 

 

16,568

 

 

477

 

 

 

2.9

 

%

Amortization of intangibles (Corporate)

109

 

 

 

149

 

 

(40

)

 

 

(26.8

)

%

Operating income (loss):

 

 

 

 

 

 

Construction

4,347

 

 

 

398

 

 

3,949

 

 

 

992.2

 

%

Service

3,083

 

 

 

1,900

 

 

1,183

 

 

 

62.3

 

%

Corporate

(413

)

 

 

(642

)

 

229

 

 

 

(35.7

)

%

Total operating income

$

7,017

 

 

 

$

1,656

 

 

$

5,361

 

 

 

323.7

 

%

 

 

 

 

 

 

 

(1) Starting January 1, 2020, we changed the methodology in which we present our corporate selling, general and administrative expenses to our CODM to better reflect the way the business is managed. Under this new methodology, all corporate expenses except for stock-based compensation are allocated to our Construction and Service segments. For comparability purposes, we reclassified our selling, general and administrative expense segment amounts for the three months ended September 30, 2019 to align with this updated allocation methodology.

 

LIMBACH HOLDINGS, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

 

Nine months ended

September 30,

 

Increase/(Decrease)

 

2020

 

2019

 

 

 

 

(in thousands)

 

 

(As Recast)

 

$

 

%

Statement of Operations Data:

 

 

 

 

 

 

 

Revenue:

 

 

 

 

 

 

 

Construction

$

345,921

 

 

 

$

327,643

 

 

 

18,278

 

 

 

5.6

 

%

Service

91,892

 

 

 

86,826

 

 

 

5,066

 

 

 

5.8

 

%

Total revenue

437,813

 

 

 

414,469

 

 

 

23,344

 

 

 

5.6

 

%

 

 

 

 

 

 

 

 

Gross profit:

 

 

 

 

 

 

 

Construction

38,043

 

 

 

34,742

 

 

 

3,301

 

 

 

9.5

 

%

Service

24,687

 

 

 

20,949

 

 

 

3,738

 

 

 

17.8

 

%

Total gross profit

62,730

 

 

 

55,691

 

 

 

7,039

 

 

 

12.6

 

%

 

 

 

 

 

 

 

 

Selling, general and administrative expenses:(1)

 

 

 

 

 

 

 

Construction

28,700

 

 

 

32,427

 

 

 

(3,727

)

 

 

(11.5

)

%

Service

18,157

 

 

 

15,890

 

 

 

2,267

 

 

 

14.3

 

%

Corporate

739

 

 

 

1,374

 

 

 

(635

)

 

 

(46.2

)

%

Total selling, general and administrative expenses

47,596

 

 

 

49,691

 

 

 

(2,095

)

 

 

(4.2

)

%

Amortization of intangibles (Corporate)

526

 

 

 

499

 

 

 

27

 

 

 

5.4

 

%

Operating income (loss):

 

 

 

 

 

 

 

Construction

9,343

 

 

 

2,315

 

 

 

7,028

 

 

 

303.6

 

%

Service

6,530

 

 

 

5,059

 

 

 

1,471

 

 

 

29.1

 

%

Corporate

(1,265

)

 

 

(1,873

)

 

 

608

 

 

 

(32.5

)

%

Total operating income

$

14,608

 

 

 

$

5,501

 

 

 

$

9,107

 

 

 

165.6

 

%

 

(1) Starting January 1, 2020, we changed the methodology in which we present our corporate selling, general and administrative expenses to our CODM to better reflect the way the business is managed. Under this new methodology, all corporate expenses except for stock-based compensation are allocated to our Construction and Service segments. For comparability purposes, we reclassified our selling, general and administrative expense segment amounts for the three months ended September 30, 2019 to align with this updated allocation methodology.

Non-GAAP Financial Measures

In assessing the performance of our business, management utilizes a variety of financial and performance measures. The key measure is Adjusted EBITDA, a non-GAAP financial measure. We define Adjusted EBITDA as net income (loss) plus depreciation and amortization expense, interest expense, and taxes, as further adjusted to eliminate the impact of, when applicable, other non-cash items or expenses that are unusual or non-recurring that we believe do not reflect our core operating results. We believe that Adjusted EBITDA is meaningful to our investors to enhance their understanding of our financial performance for the current period and our ability to generate cash flows from operations that are available for taxes, capital expenditures and debt service. We understand that Adjusted EBITDA is frequently used by securities analysts, investors and other interested parties as a measure of financial performance and to compare our performance with the performance of other companies that report Adjusted EBITDA. Our calculation of Adjusted EBITDA, however, may not be comparable to similarly titled measures reported by other companies. When assessing our operating performance, investors and others should not consider this data in isolation or as a substitute for net income (loss) calculated in accordance with GAAP. Further, the results presented by Adjusted EBITDA cannot be achieved without incurring the costs that the measure excludes. A reconciliation of net income (loss) to Adjusted EBITDA, the most comparable GAAP measure, is provided below.

We refer to our estimated revenue on uncompleted contracts, including the amount of revenue on contracts for which work has not begun, less the revenue we have recognized under such contracts, as “backlog.” Backlog includes unexercised contract options.

 

Reconciliation of Net Income (loss) to Adjusted EBITDA

 

 

 

 

 

 

 

Three months ended

September 30,

 

Nine months ended

September 30,

(in thousands)

2020

 

2019

(As Recast)

 

2020

 

2019

(As Recast)

Net income (loss)

$

2,525

 

 

$

(2,978)

 

 

$

5,420

 

 

$

(2,420)

 

 

 

 

 

 

 

 

 

Adjustments:

 

 

 

 

 

 

 

Depreciation and amortization

1,495

 

 

1,362

 

 

4,635

 

 

4,234

 

Interest expense

2,154

 

 

1,759

 

 

6,449

 

 

4,190

 

Non-cash stock-based compensation expense

304

 

 

491

 

 

739

 

 

1,373

 

Loss on debt extinguishment

 

 

 

 

 

 

513

 

Impairment of goodwill

 

 

4,359

 

 

 

 

4,359

 

Change in fair value of warrants

1,371

 

 

(525)

 

 

1,312

 

 

(422)

 

Severance expense

 

 

 

 

622

 

 

Income tax (benefit) provision

970

 

 

(942)

 

 

1,445

 

 

(681)

 

CFO transition costs

 

 

301

 

 

 

301

Adjusted EBITDA

$

8,819

 

 

$

3,827

 

 

$

20,622

 

 

$

11,447

 

 

Investor Relations:

The Equity Group, Inc.

Jeremy Hellman, CFA

Vice President

(212) 836-9626 / [email protected]

or

Limbach Holdings, Inc.

S. Mathew Katz

Executive Vice President

(212) 201-7006 / [email protected]

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Engineering Construction & Property Building Systems Manufacturing

MEDIA:

Logo
Logo

OpGen Group Company Ares Genetics Commercially Launches NGS-based Antibiotic Resistance Testing Service for Native Specimens and Receives Bulk Order from Public Health Agency

Early access program launched for the next generation of the ARESupa Universal Pathogenome Assay based on targeted next-generation sequencing (NGS) of native specimens

First commercial orders completed, assay design based on proprietary ARESdb to comprehensively cover antibiotic resistance markers

Received bulk order from public health agency

GAITHERSBURG, Md. and VIENNA, Austria, Nov. 12, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today that its group company and wholly owned subsidiary Ares Genetics GmbH (Vienna, Austria; “Ares Genetics”) launched an early access program for its novel, NGS-based molecular antibiotic resistance (AMR) test for comprehensive profiling of genetic AMR markers from native specimen by a hybrid-capture based targeted NGS assay.

Information on genetic antibiotic resistance of pathogens is critical for clinical practice, epidemiology and public health purposes as well as for the development of pharmaceutical products in the infectious disease sector. Ares Genetics therefore has developed a molecular test for comprehensive detection of genetic AMR markers from native specimen. It is an expanded version of the award-winning ARESupa Universal Pathogenome Assay that was initially launched in 2019 for the identification of pathogens and AMR genes from bacterial isolates and shown to also accurately predict antibiotic susceptibility in a multi-center U.S. study earlier this year.

The new version of the ARESupa, which for the time being is available for Research Use Only (RUO), combines hybrid-capture NGS technology for targeted detection of AMR markers and is designed for use with complex native specimen and has already been applied to various clinical and environmental sample material. The design of the assay and NGS capture probes is based on Ares Genetics’ proprietary ARESdb, a unique reference database on genetic antimicrobial resistance markers. The ARESupa for complex native specimen combines targeted NGS with data analysis and interpretation powered by ARESdb. Ares Genetics’ reference database covers genomes of more than 55,000 bacterial strains as well as associated susceptibility data for more than 100 different antibiotics and enables translation of detected AMR genes into actionable insights. Already today, Ares Genetics has received commercial orders for hundreds of the novel ARESupa tests, exceeding a bulk order volume of US$ 250,000. We believe these initial orders demonstrate the need for universal AMR profiling of native samples.

“The commercial launch of our Universal Pathogenome Assay for native specimen adds another great milestone in our fight against spreading antibiotic resistance, one of the most challenging threats to modern healthcare globally,” commented Dr. Andreas Posch, CEO Ares Genetics. “We are very pleased with our continued commercial progress facilitated by our R&D achievements, executing on our strategy to provide scalable laboratory testing solutions in combination with AI-powered cloud-based data interpretation to enable accurate molecular antibiotic resistance testing,” he added.

About OpGen, Inc.

OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit www.opgen.com.

Forward-Looking Statements by OpGen

This press release includes statements regarding the launch of an early access program next-generation sequencing based antibiotic resistance testing from complex native specimen by OpGen’s subsidiary Ares Genetics GmbH for research use only. These statements and other statements regarding OpGen’s future plans and goals constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen’s business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen Contact:

Oliver Schacht
CEO
[email protected]

Press Contact:

Matthew Bretzius
FischTank Marketing and PR
[email protected]

Investor Contact:

Megan Paul
Edison Group
[email protected]